ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%

IMMUCELL CORP /DE/

2024-Q2 EPS reported -$0.25 revenue$12,730,467

Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.
Six-month sales $12.73M, up 82% from $6.98M; twelve-month sales $23.22M, up 48%.
Backlog of orders as of June 30, 2024: approx. $8.93M.
Production output at 74% of $30M full capacity in Q2; goal to produce $14M in H2 to reach ~95%.
Still working on FDA approval for Re-Tain; expect fourth CMC submission after manufacturer issues resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.